Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) EBITDA: 2022-2025

Historic EBITDA for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$38.0 million.

  • Stoke Therapeutics' EBITDA fell 44.76% to -$38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.8 million, marking a year-over-year increase of 138.85%. This contributed to the annual value of -$89.1 million for FY2024, which is 13.95% up from last year.
  • Per Stoke Therapeutics' latest filing, its EBITDA stood at -$38.0 million for Q3 2025, which was down 63.20% from -$23.3 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' EBITDA peaked at $112.9 million during Q1 2025, and registered a low of -$38.0 million during Q3 2025.
  • Over the past 3 years, Stoke Therapeutics' median EBITDA value was -$25.7 million (recorded in 2024), while the average stood at -$12.8 million.
  • The largest annual percentage gain for Stoke Therapeutics' EBITDA in the last 5 years was 528.56% (2025), contrasted with its biggest fall of 44.76% (2025).
  • Quarterly analysis of 4 years shows Stoke Therapeutics' EBITDA stood at -$25.1 million in 2022, then fell by 6.80% to -$26.8 million in 2023, then skyrocketed by 59.76% to -$10.8 million in 2024, then slumped by 44.76% to -$38.0 million in 2025.
  • Its last three reported values are -$38.0 million in Q3 2025, -$23.3 million for Q2 2025, and $112.9 million during Q1 2025.